CGiddy, I agree that it is awesome being a CYDY investor these days. Brazil is a win & will result in revenue. So unusual for a biotech to have revenue pre-approval, as many do not have significant revenue post approval.
Something that may have been discussed previously ( been quite busy) that is on my mind is PI presentation. At first I was underwhelmed. Then realized that Chiral ( who did an excellent job) had gone to great effort to bring in those previously not familiar with CYDY. The questions they asked made it obvious that they were professionals & humanitarians not previously aware of LL& it's MOA.
Do you think the re-visit to PI was requested from there (Chiral) or maybe the new pr firm seeing opportunity where there has already been discussion or interest?
I feel that when you consider NP's comments, pr company has advised company to go "one brick at a time". Donot move on prior to maximizing current indication. Thoughts? We can't lose!